Högskolan i Skövde

his.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • apa-cv
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Inferring disease course from differential exon usage in the wide titinopathy spectrum
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health (DINOGMI), University of Genoa, Italy ; Folkhälsan Research Center, Uusimaa, Helsinki, Finland.
Folkhhälsan Research Center, Helsinki, Uusimaa, Finland.
Folkhhälsan Research Center, Helsinki, Uusimaa, Finland.
Randall Division of Cell and Molecular Biophysics and Cardiovascular Division, King’s College London BHF Centre of Research Excellence, London, UK.
Show others and affiliations
2024 (English)In: Annals of Clinical and Translational Neurology, E-ISSN 2328-9503, Vol. 11, no 10, p. 2745-2755Article in journal (Refereed) Published
Abstract [en]

Objective: Biallelic titin truncating variants (TTNtv) have been associated with a wide phenotypic spectrum, ranging from complex prenatal muscle diseases with dysmorphic features to adult-onset limb-girdle muscular dystrophy, with or without cardiac involvement. Given the size and complexity of TTN, reaching an unequivocal molecular diagnosis and precise disease prognosis remains challenging. Methods: In this case series, 12 unpublished cases and one already published case with biallelic TTNtv were collected from multiple international medical centers between November 2022 and September 2023. TTN mutations were detected through exome or genome sequencing. Information about familial and personal clinical history was collected in a standardized form. RNA-sequencing and analysis of TTN exon usage were performed on an internal sample cohort including postnatal skeletal muscles, fetal skeletal muscles, postnatal heart muscles, and fetal heart muscles. In addition, publicly available RNA-sequencing data was retrieved from ENCODE. Results: We generated new RNA-seq data on TTN exons and identified genotype–phenotype correlations with prognostic implications for each titinopathy patient (whether worsening or improving in prenatal and postnatal life) using percentage spliced in (PSI) data for the involved exons. Interestingly, thanks to exon usage, we were also able to rule out a titinopathy diagnosis in one prenatal case. Interpretation: This study demonstrates that exon usage provides valuable insights for a more exhaustive clinical interpretation of TTNtv; additionally, it may serve as a model for implementing personalized medicine in many other genetic diseases, since most genes undergo alternative splicing. 

Place, publisher, year, edition, pages
John Wiley & Sons, 2024. Vol. 11, no 10, p. 2745-2755
National Category
Medical Genetics and Genomics Neurology Bioinformatics and Computational Biology
Research subject
Translational Medicine TRIM
Identifiers
URN: urn:nbn:se:his:diva-24485DOI: 10.1002/acn3.52189ISI: 001299553100001PubMedID: 39198997Scopus ID: 2-s2.0-85202521250OAI: oai:DiVA.org:his-24485DiVA, id: diva2:1895263
Funder
Academy of Finland, 339437Academy of Finland
Note

CC BY 4.0

First published: 28 August 2024

© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Correspondence Address: M.F. Di Feo; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy; email: mariafrancescadifeo@gaslini.org

M.S. received support from the Academy of Finland (grant 339437), Association Française contre les Myopathies (grant 23281), Sydäntutkimussäätiö, and Samfundet Folkhälsan i Svenska, Finland. A.O. received supported by Magnus Ehrnrooth Foundation. B.U. received support from the European Joint Program on Rare Diseases (project IDOLS-G), Academy of Finland, Juselius Foundation, and Samfundet Folkhälsan i Svenska Finland. F.M. received support from the European Joint Program on Rare Diseases (project IDOLS-G) and Instituto de Salud Carlos III, Spain (project number AC19/00048). P.H. received support from the Jane and Aatos Erkko foundation.

Available from: 2024-09-05 Created: 2024-09-05 Last updated: 2025-02-10Bibliographically approved

Open Access in DiVA

fulltext(751 kB)76 downloads
File information
File name FULLTEXT02.pdfFile size 751 kBChecksum SHA-512
f5ce7dba9a667b6030267cb04f212ccaeb43b973ac369c1bfa03b7c6da26c2cb6af72f5841efc23de3802ed42e7ecc458df5a3fb61b780c2e06971f26250eb45
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Tajsharghi, Homa

Search in DiVA

By author/editor
Tajsharghi, Homa
By organisation
School of Health SciencesDigital Health Research (DHEAR)
In the same journal
Annals of Clinical and Translational Neurology
Medical Genetics and GenomicsNeurologyBioinformatics and Computational Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 92 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 194 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • apa-cv
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf